Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic medicines, including IOPIDINE and MOXEZA; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection drug candidate. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Legends:
Stock price
- -
Beta (1.0 Market)
% total return 05/17
Stock
S&P500
YTD
-34.57
- -
3Y
51.39
- -
5Y
131.42
- -
-0.46EPS Dil.
-34.97P/E
567.51MMarket Cap
Capital Structure
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
ST Debt
1
1
1
LT Borrowings
169
170
182
LT Finance Leases
7
7
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
35
Market Capitalization
636
576
505
Working Capital
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
52
60
110
Cash, Cash Equivalents & STI
27
30
74
Accounts Receivable, Net
12
18
18
Inventories
9
9
9
Total Current Liabilities
18
23
19
Payables & Accruals
17
22
18
ST Debt
1
1
1
Deferred Revenue
0
0
0
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
- -
0.02
0.00
0.18
1.01
1.56
1.34
1.89
2.02
1.89
2.71
3.23
3.71
Revenue per ShareRevenue per Share
- -
-8.91
-11.68
-6.41
-2.65
-1.24
-0.88
-1.11
-1.66
-1.50
-0.60
0.67
0.01
-0.13
-0.69
-0.51
-0.46
Basic EPS, GAAPBasic EPS, GAAP
- -
-6.84
-9.16
-5.82
-0.73
-0.43
-0.52
-0.79
-1.29
-1.44
-0.49
-0.07
-0.04
-0.08
-0.41
-0.22
-5.43
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.04
- -
- -
- -
- -
- -
- -
- -
- -
0.00
- -
- -
Dividend per ShareDividend per Share
- -
-26.65
-38.16
-43.85
-46.49
-3.56
-3.54
-4.52
-5.92
-4.12
-4.31
-3.05
-2.90
-3.00
-3.55
-3.66
-3.55
Book Value per ShareBook Value per Share
- -
11.75
1.48
-2.61
-4.27
1.48
1.68
0.78
-0.72
0.07
-0.12
0.80
0.97
0.95
-0.24
0.04
-2.56
Tangible Book Value per ShareTangible Book Value per Share